Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Research & Development (2020 - 2025)

Lyell Immunopharma's Research & Development history spans 6 years, with the latest figure at $28.2 million for Q3 2025.

  • For Q3 2025, Research & Development fell 28.68% year-over-year to $28.2 million; the TTM value through Sep 2025 reached $155.1 million, down 8.7%, while the annual FY2024 figure was $171.6 million, 6.2% down from the prior year.
  • Research & Development for Q3 2025 was $28.2 million at Lyell Immunopharma, down from $34.9 million in the prior quarter.
  • Across five years, Research & Development topped out at $48.7 million in Q4 2024 and bottomed at $19.3 million in Q4 2021.
  • The 5-year median for Research & Development is $41.6 million (2022), against an average of $39.9 million.
  • The largest annual shift saw Research & Development soared 19185.0% in 2021 before it decreased 28.68% in 2025.
  • A 5-year view of Research & Development shows it stood at $19.3 million in 2021, then skyrocketed by 97.21% to $38.0 million in 2022, then grew by 23.57% to $47.0 million in 2023, then grew by 3.56% to $48.7 million in 2024, then plummeted by 42.11% to $28.2 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Research & Development are $28.2 million (Q3 2025), $34.9 million (Q2 2025), and $43.4 million (Q1 2025).